A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2018-02-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open label study to assess the safety and efficacy of tocilizumab in group 1 pulmonary arterial hypertension patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688

PAH Pulmonary Hypertension Pulmonary Arterial Hypertension +8 more

COMPLETED PHASE3

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

NCT04896008

Pulmonary Arterial Hypertension

COMPLETED PHASE3

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366

Pulmonary Arterial Hypertension

TERMINATED PHASE2

A Study to Evaluate GSK1325760A - a Long-Term Extension Study

NCT00554619

Pulmonary Arterial Hypertension Hypertension, Pulmonary

COMPLETED PHASE3

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Pulmonary Arterial Hypertension (PAH) raised blood pressure in the lungs leads to heart failure and early death. Patients not only have a significantly reduced life expectancy, but their quality of life is severely affected. If left untreated life expectancy is 2-3 years. Current treatments all aim to relax the vessels in the lung and lower the blood pressures, however none target the causes of the disease and currently there is not cure. Despite the availability of treatments the impact on mortality has been modest at best with one third of patients still dying within two years of diagnosis. There remains an urgent need to test new ways of treating PAH.

PAH is often associated with auto-immune diseases (when the bodies own system attacks itself rather than fight infection). Targeting components of the immune system involved in the development of disease offer a potential new area of treatment for PAH; an example known to be involved in the progression of PAH is the protein Interleukin-6 (IL-6). Tocilizumab is a drug which blocks the action of Interleukin-6 and blocking Interleukin-6 has been shown to be effective in animal models of PAH. Tocilizumab was demonstrated to be safe and effective in trials in other diseases associated with PAH, such as rheumatoid arthritis.

This study is a 6 month open label phase II trial of IV Tocilizumab in 21 patients with group 1 PAH. The aim of the trial is to see if Tocilizumab is safe and whether it reduces the blood pressure in the lungs. Patients will be given Tocilizumab intravenously once a month for six months with close safety monitoring. The trial will be led by Papworth Hospital and a total of 7 UK specialist centres will take part. The trial will assess the safety of the drug and response to treatment by measuring heart function, blood pressure in the lungs, exercise capacity and quality of life measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open Label

Intravenous Tocilizumab 8mg/kg monthly (up to a maximum dose 800mg) for 6 months

Group Type EXPERIMENTAL

Tocilizumab

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tocilizumab

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RoActemra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group 1 PAH due to: Idiopathic or Heritable PAH, PAH associated with connective tissue disease excluding SLE, RA and mixed CTD, Drug and Toxins
* WHO functional class II-IV
* Weight more than 40kg
* 6 minute walk distance of 100-500 m
* Haemodynamic criteria measure by RHC
* Documented negative V/Q scan or pulmonary arteriogram confirming absence of chromic thromboembolic disease
* Resting oxygen saturations of \>85%
* Lung function confirming absence of significant lung disease
* Stable on unchanged PAH therapeutic regime for at least 1 month

Exclusion Criteria

* Subjects on continuous infusions either intravenously or subcutaneously
* Hypersensitivity to Investigational Product
* Severe hepatic impairment
* Severe renal impairment
* Clinically significant anaemia
* Blood platelets \<100x10
* Neutrophil count \<2x10/L
* Left ventricular disease/dysfunction risk factors
* Myocardial infarction within 90 days prior to screening
* Female subjects who are pregnant or breastfeeding
* History of malignancies within past 5 years

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No